Back to results

LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2 (LAPLACE-2)

Primary Purpose

Hyperlipidemia

Status

Completed

Phase

Phase 3

Locations

International

Study Type

Interventional

Intervention

Evolocumab

Ezetimibe

Placebo to Evolocumab

Placebo to Ezetimibe

Atorvastatin

Rosuvastatin

Simvastatin

About this trial

This is an interventional treatment trial for Hyperlipidemia focused on measuring High cholesterol, Treatment for high cholesterol, Lowering cholesterol, Lowering high cholesterol, Hypercholesterolemia

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Male or female ≥ 18 to ≤ 80 years of age
Subjects not taking a statin must have fasting LDL-C of at least 150 mg/dL (4.0 mmol/L)
Subjects already on a non-intensive statin must have fasting LDL-C at screening ≥ 100 mg/dL (2.6 mmol/L)
Subjects already on a intensive statin must have fasting LDL-C at screening ≥ 80 mg/dL (2.1 mmol/L)
Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L)

Exclusion Criteria:

Statin intolerance
New York Heart association (NYHA) III or IV heart failure
Uncontrolled hypertension
Uncontrolled cardiac arrhythmia
Type 1 diabetes, poorly controlled type 2 diabetes
Uncontrolled hypothyroidism or hyperthyroidism

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm 10

Arm 11

Arm 12

Arm 13

Arm 14

Arm 15

Arm 16

Arm 17

Arm 18

Arm 19

Arm 20

Arm 21

Arm 22

Arm 23

Arm 24

Arm Type

Placebo Comparator

Active Comparator

Experimental

Placebo Comparator

Active Comparator

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Experimental

Arm Label

A10 PBO Q2W

A10 PBO QM

A10 EZE (Q2W)

A10 EZE (QM)

A10 EvoMab Q2W

A10 EvoMab QM

A80 PBO Q2W

A80 PBO QM

A80 EZE (Q2W)

A80 EZE (QM)

A80 EvoMab Q2W

A80 EvoMab QM

R5 PBO Q2W

R5 PBO QM

R5 EvoMab Q2W

R5 EvoMab QM

R40 PBO Q2W

R40 PBO QM

R40 EvoMab Q2W

R40 EvoMab QM

S40 PBO Q2W

S40 PBO QM

S40 EvoMab Q2W

S40 EvoMab QM

Arm Description

Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.

Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.

Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once a day for up to 12 weeks.

Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.

Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.

Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks

Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.

Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month and placebo tablets once a day for up to 12 weeks.

Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.

Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.

Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.

Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.

Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.

Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month for up to 12 weeks.

Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.

Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.

Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.

Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month for up to 12 weeks.

Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.

Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.

Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.

Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month for up to 12 weeks.

Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.

Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.

Outcomes

Primary Outcome Measures

Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12

Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12

Secondary Outcome Measures

Change From Baseline in LDL-C at at the Mean of Weeks 10 and 12

Change From Baseline in LDL-C at Week 12

Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 10 and 12

Percent Change From Baseline in Non-HDL-C at Week 12

Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12

Percent Change From Baseline in Apolipoprotein B at Week 12

Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12

Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12

Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12

Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12

Percentage of Participants Who Achieved a Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL

Percentage of Participants Who Achieved LDL-C < 70 mg/dL at Week 12

Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12

Percent Change From Baseline in Lipoprotein(a) at Week 12

Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12

Percent Change From Baseline in Triglycerides at Week 12

Percent Change From Baseline in Very Low-Density Cholesterol (VLDL-C) at the Mean of Weeks 10 and 12

Percent Change From Baseline in Very Low-Density Cholesterol (VLDL-C) at Week 12

Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12

Percent Change From Baseline in HDL-C at Week 12

Full Information

NCT ID

NCT01763866

First Posted

January 7, 2013

Last Updated

November 4, 2022

Sponsor

Amgen

1. Study Identification

Unique Protocol Identification Number

NCT01763866

Brief Title

LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2

Acronym

LAPLACE-2

Official Title

A Double-blind, Randomized, Placebo and Ezetimibe Controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Combination With Statin Therapy in Subjects With Primary Hypercholesterolemia and Mixed Dyslipidemia

Study Type

Interventional

2. Study Status

Record Verification Date

November 2022

Overall Recruitment Status

Completed

Study Start Date

January 15, 2013 (Actual)

Primary Completion Date

November 12, 2013 (Actual)

Study Completion Date

December 4, 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Amgen

4. Oversight

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

The primary objective was to evaluate the effect of 12 weeks of evolocumab administered subcutaneously every 2 weeks (Q2W) and monthly (QM) when used in combination with a statin, compared with placebo, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia.

Detailed Description

Prior to the first randomization, participants entered a screening period to determine eligibility. During screening, all participants received subcutaneous placebo corresponding to the once monthly dose volume. Participants who completed the screening period and met eligibility criteria were randomized to 1 of 5 open-label statin cohorts (atorvastatin 10 mg or 80 mg, rosuvastatin 5 mg or 40 mg, or simvastatin 40 mg) for a 4 week lipid stabilization period based on statin therapy at the time of study entry (no statin use vs non-intensive statin use vs intensive statin use). After the 4-week lipid-stabilization period, eligible patients taking rosuvastatin or simvastatin during the lipid-stabilization phase were then randomized to 1 of 4 treatment groups: evolocumab (140 mg, subcutaneous, every 2 weeks) or matching placebo (subcutaneous, every 2 weeks), or evolocumab (420 mg, subcutaneous, monthly) or matching placebo (subcutaneous, monthly). Patients taking atorvastatin during the lipid-stabilization phase were then randomized to 1 of 6 treatment groups: evolocumab (140 mg, subcutaneous, every 2 weeks) and placebo (oral, daily), evolocumab (420 mg, subcutaneous, monthly) and placebo (oral, daily), placebo (subcutaneous, every 2 weeks) and placebo (oral, daily) or ezetimibe (10 mg, oral, daily), or placebo (subcutaneous, monthly) and placebo (oral, daily) or ezetimibe (10 mg, oral, daily). A participant was considered randomized into the study after successfully completing the screening period, meeting all inclusion/exclusion criteria, and undergoing both randomization procedures. Participants randomized to simvastatin who were taking verapamil or diltiazem prior to randomization received simvastatin 10 mg once daily (QD) while participants who were taking amlodipine, amiodarone or ranolazine prior to randomization received simvastatin 20 mg QD. All other participants randomized to simvastatin received simvastatin 40 mg QD.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Hyperlipidemia

Keywords

High cholesterol, Treatment for high cholesterol, Lowering cholesterol, Lowering high cholesterol, Hypercholesterolemia

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 3

Interventional Study Model

Parallel Assignment

Masking

ParticipantCare ProviderInvestigatorOutcomes Assessor

Allocation

Randomized

Enrollment

2067 (Actual)

8. Arms, Groups, and Interventions

Arm Title

A10 PBO Q2W

Arm Type

Placebo Comparator

Arm Description

Arm Title

A10 PBO QM

Arm Type

Placebo Comparator

Arm Description

Arm Title

A10 EZE (Q2W)

Arm Type

Active Comparator

Arm Description

Arm Title

A10 EZE (QM)

Arm Type

Active Comparator

Arm Description

Arm Title

A10 EvoMab Q2W

Arm Type

Experimental

Arm Description

Arm Title

A10 EvoMab QM

Arm Type

Experimental

Arm Description

Arm Title

A80 PBO Q2W

Arm Type

Placebo Comparator

Arm Description

Arm Title

A80 PBO QM

Arm Type

Placebo Comparator

Arm Description

Arm Title

A80 EZE (Q2W)

Arm Type

Active Comparator

Arm Description

Arm Title

A80 EZE (QM)

Arm Type

Active Comparator

Arm Description

Arm Title

A80 EvoMab Q2W

Arm Type

Experimental

Arm Description

Arm Title

A80 EvoMab QM

Arm Type

Experimental

Arm Description

Arm Title

R5 PBO Q2W

Arm Type

Placebo Comparator

Arm Description

Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.

Arm Title

R5 PBO QM

Arm Type

Placebo Comparator

Arm Description

Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month for up to 12 weeks.

Arm Title

R5 EvoMab Q2W

Arm Type

Experimental

Arm Description

Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.

Arm Title

R5 EvoMab QM

Arm Type

Experimental

Arm Description

Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.

Arm Title

R40 PBO Q2W

Arm Type

Placebo Comparator

Arm Description

Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.

Arm Title

R40 PBO QM

Arm Type

Placebo Comparator

Arm Description

Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month for up to 12 weeks.

Arm Title

R40 EvoMab Q2W

Arm Type

Experimental

Arm Description

Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.

Arm Title

R40 EvoMab QM

Arm Type

Experimental

Arm Description

Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.

Arm Title

S40 PBO Q2W

Arm Type

Placebo Comparator

Arm Description

Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.

Arm Title

S40 PBO QM

Arm Type

Placebo Comparator

Arm Description

Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month for up to 12 weeks.

Arm Title

S40 EvoMab Q2W

Arm Type

Experimental

Arm Description

Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.

Arm Title

S40 EvoMab QM

Arm Type

Experimental

Arm Description

Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.

Intervention Type

Biological

Intervention Name(s)

Evolocumab

Other Intervention Name(s)

AMG 145, Repatha

Intervention Description

Administered by subcutaneous injection

Intervention Type

Drug

Intervention Name(s)

Ezetimibe

Other Intervention Name(s)

Zetia

Intervention Description

Administered orally once a day

Intervention Type

Drug

Intervention Name(s)

Placebo to Evolocumab

Intervention Description

Administered by subcutaneous injection

Intervention Type

Drug

Intervention Name(s)

Placebo to Ezetimibe

Intervention Description

Administered orally once a day

Intervention Type

Drug

Intervention Name(s)

Atorvastatin

Other Intervention Name(s)

Lipitor

Intervention Description

Administered orally once a day

Intervention Type

Drug

Intervention Name(s)

Rosuvastatin

Other Intervention Name(s)

Crestor

Intervention Description

Administered orally once a day

Intervention Type

Drug

Intervention Name(s)

Simvastatin

Other Intervention Name(s)

Zocor

Intervention Description

Administered orally once a day

Primary Outcome Measure Information:

Title

Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12

Time Frame

Baseline and Week 12

Title

Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12

Time Frame

Baseline and Weeks 10 and 12

Secondary Outcome Measure Information:

Title

Change From Baseline in LDL-C at at the Mean of Weeks 10 and 12

Time Frame

Baseline and Weeks 10 and 12

Title

Change From Baseline in LDL-C at Week 12

Time Frame

Baseline and Week 12

Title

Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 10 and 12

Time Frame

Baseline and Weeks 10 and 12

Title

Percent Change From Baseline in Non-HDL-C at Week 12

Time Frame

Baseline and Week 12

Title

Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12

Time Frame

Baseline and Weeks 10 and 12

Title

Percent Change From Baseline in Apolipoprotein B at Week 12

Time Frame

Baseline and Week 12

Title

Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12

Time Frame

Baseline and Weeks 10 and 12

Title

Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12

Time Frame

Baseline and Week 12

Title

Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12

Time Frame

Baseline and Weeks 10 and 12

Title

Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12

Time Frame

Baseline and Week 12

Title

Percentage of Participants Who Achieved a Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL

Time Frame

Weeks 10 and 12

Title

Percentage of Participants Who Achieved LDL-C < 70 mg/dL at Week 12

Time Frame

Week 12

Title

Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12

Time Frame

Baseline and Weeks 10 and 12

Title

Percent Change From Baseline in Lipoprotein(a) at Week 12

Time Frame

Baseline and Week 12

Title

Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12

Time Frame

Baseline and Weeks 10 and 12

Title

Percent Change From Baseline in Triglycerides at Week 12

Time Frame

Baseline and Week 12

Title

Percent Change From Baseline in Very Low-Density Cholesterol (VLDL-C) at the Mean of Weeks 10 and 12

Time Frame

Baseline and Weeks 10 and 12

Title

Percent Change From Baseline in Very Low-Density Cholesterol (VLDL-C) at Week 12

Time Frame

Baseline and Week 12

Title

Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12

Time Frame

Baseline and Weeks 10 and 12

Title

Percent Change From Baseline in HDL-C at Week 12

Time Frame

Baseline and Week 12

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Maximum Age & Unit of Time

80 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Male or female ≥ 18 to ≤ 80 years of age Subjects not taking a statin must have fasting LDL-C of at least 150 mg/dL (4.0 mmol/L) Subjects already on a non-intensive statin must have fasting LDL-C at screening ≥ 100 mg/dL (2.6 mmol/L) Subjects already on a intensive statin must have fasting LDL-C at screening ≥ 80 mg/dL (2.1 mmol/L) Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L) Exclusion Criteria: Statin intolerance New York Heart association (NYHA) III or IV heart failure Uncontrolled hypertension Uncontrolled cardiac arrhythmia Type 1 diabetes, poorly controlled type 2 diabetes Uncontrolled hypothyroidism or hyperthyroidism

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Organizational Affiliation

Amgen

Official's Role

Study Director

Facility Information:

Facility Name

Research Site

City

Birmingham

State/Province

Alabama

ZIP/Postal Code

35294

Country

United States

Facility Name

Research Site

City

Glendale

State/Province

Arizona

ZIP/Postal Code

85306

Country

United States

Facility Name

Research Site

City

Tucson

State/Province

Arizona

ZIP/Postal Code

85710

Country

United States

Facility Name

Research Site

City

Tucson

State/Province

Arizona

ZIP/Postal Code

85712

Country

United States

Facility Name

Research Site

City

Carmichael

State/Province

California

ZIP/Postal Code

95608

Country

United States

Facility Name

Research Site

City

Encino

State/Province

California

ZIP/Postal Code

91436

Country

United States

Facility Name

Research Site

City

Long Beach

State/Province

California

ZIP/Postal Code

90822

Country

United States

Facility Name

Research Site

City

Newport Beach

State/Province

California

ZIP/Postal Code

92663

Country

United States

Facility Name

Research Site

City

San Diego

State/Province

California

ZIP/Postal Code

92123

Country

United States

Facility Name

Research Site

City

Santa Ana

State/Province

California

ZIP/Postal Code

92705

Country

United States

Facility Name

Research Site

City

Santa Rosa

State/Province

California

ZIP/Postal Code

95405

Country

United States

Facility Name

Research Site

City

Thousand Oaks

State/Province

California

ZIP/Postal Code

91360

Country

United States

Facility Name

Research Site

City

Torrance

State/Province

California

ZIP/Postal Code

90509

Country

United States

Facility Name

Research Site

City

Tustin

State/Province

California

ZIP/Postal Code

92780

Country

United States

Facility Name

Research Site

City

Westlake Village

State/Province

California

ZIP/Postal Code

91361

Country

United States

Facility Name

Research Site

City

Littleton

State/Province

Colorado

ZIP/Postal Code

80120

Country

United States

Facility Name

Research Site

City

Daytona Beach

State/Province

Florida

ZIP/Postal Code

32117

Country

United States

Facility Name

Research Site

City

Jacksonville

State/Province

Florida

ZIP/Postal Code

32223

Country

United States

Facility Name

Research Site

City

Melbourne

State/Province

Florida

ZIP/Postal Code

32901

Country

United States

Facility Name

Research Site

City

Miami

State/Province

Florida

ZIP/Postal Code

33173

Country

United States

Facility Name

Research Site

City

Port Charlotte

State/Province

Florida

ZIP/Postal Code

33952

Country

United States

Facility Name

Research Site

City

Atlanta

State/Province

Georgia

ZIP/Postal Code

30328

Country

United States

Facility Name

Research Site

City

Atlanta

State/Province

Georgia

ZIP/Postal Code

30342

Country

United States

Facility Name

Research Site

City

Boise

State/Province

Idaho

ZIP/Postal Code

83704

Country

United States

Facility Name

Research Site

City

Hammond

State/Province

Indiana

ZIP/Postal Code

46320

Country

United States

Facility Name

Research Site

City

Indianapolis

State/Province

Indiana

ZIP/Postal Code

46237

Country

United States

Facility Name

Research Site

City

Valparaiso

State/Province

Indiana

ZIP/Postal Code

46383

Country

United States

Facility Name

Research Site

City

Iowa City

State/Province

Iowa

ZIP/Postal Code

52242

Country

United States

Facility Name

Research Site

City

Crestview Hills

State/Province

Kentucky

ZIP/Postal Code

41017

Country

United States

Facility Name

Research Site

City

Monroe

State/Province

Louisiana

ZIP/Postal Code

71203

Country

United States

Facility Name

Research Site

City

Auburn

State/Province

Maine

ZIP/Postal Code

04210

Country

United States

Facility Name

Research Site

City

Bangor

State/Province

Maine

ZIP/Postal Code

04401

Country

United States

Facility Name

Research Site

City

Portland

State/Province

Maine

ZIP/Postal Code

04101

Country

United States

Facility Name

Research Site

City

Baltimore

State/Province

Maryland

ZIP/Postal Code

21201

Country

United States

Facility Name

Research Site

City

Ypsilanti

State/Province

Michigan

ZIP/Postal Code

48197

Country

United States

Facility Name

Research Site

City

Tupelo

State/Province

Mississippi

ZIP/Postal Code

38801

Country

United States

Facility Name

Research Site

City

Billings

State/Province

Montana

ZIP/Postal Code

59102

Country

United States

Facility Name

Research Site

City

Voorhees

State/Province

New Jersey

ZIP/Postal Code

08043

Country

United States

Facility Name

Research Site

City

Manlius

State/Province

New York

ZIP/Postal Code

13104

Country

United States

Facility Name

Research Site

City

Rochester

State/Province

New York

ZIP/Postal Code

14609

Country

United States

Facility Name

Research Site

City

Syracuse

State/Province

New York

ZIP/Postal Code

13210

Country

United States

Facility Name

Research Site

City

Williamsville

State/Province

New York

ZIP/Postal Code

14221

Country

United States

Facility Name

Research Site

City

Winston-Salem

State/Province

North Carolina

ZIP/Postal Code

27103

Country

United States

Facility Name

Research Site

City

Cadiz

State/Province

Ohio

ZIP/Postal Code

43907

Country

United States

Facility Name

Research Site

City

Canton

State/Province

Ohio

ZIP/Postal Code

44708

Country

United States

Facility Name

Research Site

City

Cincinnati

State/Province

Ohio

ZIP/Postal Code

45219

Country

United States

Facility Name

Research Site

City

Cincinnati

State/Province

Ohio

ZIP/Postal Code

45227

Country

United States

Facility Name

Research Site

City

Dayton

State/Province

Ohio

ZIP/Postal Code

45414

Country

United States

Facility Name

Research Site

City

Mansfield

State/Province

Ohio

ZIP/Postal Code

44906

Country

United States

Facility Name

Research Site

City

Marion

State/Province

Ohio

ZIP/Postal Code

43302

Country

United States

Facility Name

Research Site

City

Sandusky

State/Province

Ohio

ZIP/Postal Code

44870

Country

United States

Facility Name

Research Site

City

Norman

State/Province

Oklahoma

ZIP/Postal Code

73069

Country

United States

Facility Name

Research Site

City

Duncansville

State/Province

Pennsylvania

ZIP/Postal Code

16635

Country

United States

Facility Name

Research Site

City

Pittsburgh

State/Province

Pennsylvania

ZIP/Postal Code

15216

Country

United States

Facility Name

Research Site

City

York

State/Province

Pennsylvania

ZIP/Postal Code

17405

Country

United States

Facility Name

Research Site

City

Florence

State/Province

South Carolina

ZIP/Postal Code

29501

Country

United States

Facility Name

Research Site

City

Rapid City

State/Province

South Dakota

ZIP/Postal Code

57701

Country

United States

Facility Name

Research Site

City

Jackson

State/Province

Tennessee

ZIP/Postal Code

38301

Country

United States

Facility Name

Research Site

City

Jackson

State/Province

Tennessee

ZIP/Postal Code

38305

Country

United States

Facility Name

Research Site

City

Dallas

State/Province

Texas

ZIP/Postal Code

75231

Country

United States

Facility Name

Research Site

City

Houston

State/Province

Texas

ZIP/Postal Code

77074

Country

United States

Facility Name

Research Site

City

San Antonio

State/Province

Texas

ZIP/Postal Code

78229

Country

United States

Facility Name

Research Site

City

Suffolk

State/Province

Virginia

ZIP/Postal Code

23435

Country

United States

Facility Name

Research Site

City

Winchester

State/Province

Virginia

ZIP/Postal Code

22601

Country

United States

Facility Name

Research Site

City

Tacoma

State/Province

Washington

ZIP/Postal Code

98405

Country

United States

Facility Name

Research Site

City

Sydney

State/Province

New South Wales

ZIP/Postal Code

2022

Country

Australia

Facility Name

Research Site

City

Ashford

State/Province

South Australia

ZIP/Postal Code

5035

Country

Australia

Facility Name

Research Site

City

Fullarton

State/Province

South Australia

ZIP/Postal Code

5063

Country

Australia

Facility Name

Research Site

City

Fitzroy

State/Province

Victoria

ZIP/Postal Code

3065

Country

Australia

Facility Name

Research Site

City

Heidelberg Heights

State/Province

Victoria

ZIP/Postal Code

3081

Country

Australia

Facility Name

Research Site

City

Richmond

State/Province

Victoria

ZIP/Postal Code

3121

Country

Australia

Facility Name

Research Site

City

Blankenberge

ZIP/Postal Code

8370

Country

Belgium

Facility Name

Research Site

City

ChÃªnÃ©e

ZIP/Postal Code

4032

Country

Belgium

Facility Name

Research Site

City

Hasselt

ZIP/Postal Code

3500

Country

Belgium

Facility Name

Research Site

City

Oostende

ZIP/Postal Code

8400

Country

Belgium

Facility Name

Research Site

City

Tremelo

ZIP/Postal Code

3120

Country

Belgium

Facility Name

Research Site

City

Vilvoorde

ZIP/Postal Code

1800

Country

Belgium

Facility Name

Research Site

City

Burnaby

State/Province

British Columbia

ZIP/Postal Code

V5G 1T4

Country

Canada

Facility Name

Research Site

City

Kelowna

State/Province

British Columbia

ZIP/Postal Code

V1Y 1E4

Country

Canada

Facility Name

Research Site

City

Kelowna

State/Province

British Columbia

ZIP/Postal Code

V1Y 1V6

Country

Canada

Facility Name

Research Site

City

Surrey

State/Province

British Columbia

ZIP/Postal Code

V3V 1N1

Country

Canada

Facility Name

Research Site

City

Saint Johnâ€™s

State/Province

Newfoundland and Labrador

ZIP/Postal Code

A1A 3R5

Country

Canada

Facility Name

Research Site

City

Cambridge

State/Province

Ontario

ZIP/Postal Code

N1R 6V6

Country

Canada

Facility Name

Research Site

City

Hamilton

State/Province

Ontario

ZIP/Postal Code

L8L 2X2

Country

Canada

Facility Name

Research Site

City

London

State/Province

Ontario

ZIP/Postal Code

N5W 6A2

Country

Canada

Facility Name

Research Site

City

Newmarket

State/Province

Ontario

ZIP/Postal Code

L3Y 5G8

Country

Canada

Facility Name

Research Site

City

Oshawa

State/Province

Ontario

ZIP/Postal Code

L1J 2K1

Country

Canada

Facility Name

Research Site

City

Sarnia

State/Province

Ontario

ZIP/Postal Code

N7T 4X3

Country

Canada

Facility Name

Research Site

City

Scarborough

State/Province

Ontario

ZIP/Postal Code

M1P 2T7

Country

Canada

Facility Name

Research Site

City

Toronto

State/Province

Ontario

ZIP/Postal Code

M8V 3X8

Country

Canada

Facility Name

Research Site

City

Toronto

State/Province

Ontario

ZIP/Postal Code

M9V 4B4

Country

Canada

Facility Name

Research Site

City

Woodstock

State/Province

Ontario

ZIP/Postal Code

N4S 5P5

Country

Canada

Facility Name

Research Site

City

Brossard

State/Province

Quebec

ZIP/Postal Code

J4X 1S4

Country

Canada

Facility Name

Research Site

City

Greenfield Park

State/Province

Quebec

ZIP/Postal Code

J4V 2G8

Country

Canada

Facility Name

Research Site

City

Lachine

State/Province

Quebec

ZIP/Postal Code

H8S 2E4

Country

Canada

Facility Name

Research Site

City

Longueuil

State/Province

Quebec

ZIP/Postal Code

J4N 0C9

Country

Canada

Facility Name

Research Site

City

Montreal

State/Province

Quebec

ZIP/Postal Code

H4N 2W2

Country

Canada

Facility Name

Research Site

City

Pointe-Claire

State/Province

Quebec

ZIP/Postal Code

H9R 3J1

Country

Canada

Facility Name

Research Site

City

Brno

ZIP/Postal Code

602 00

Country

Czechia

Facility Name

Research Site

City

Brno

ZIP/Postal Code

603 00

Country

Czechia

Facility Name

Research Site

City

Kladno

ZIP/Postal Code

272 01

Country

Czechia

Facility Name

Research Site

City

Litomerice

ZIP/Postal Code

412 01

Country

Czechia

Facility Name

Research Site

City

Moravske Budejovice

ZIP/Postal Code

676 02

Country

Czechia

Facility Name

Research Site

City

Olomouc

ZIP/Postal Code

775 20

Country

Czechia

Facility Name

Research Site

City

Pardubice

ZIP/Postal Code

530 02

Country

Czechia

Facility Name

Research Site

City

Praha 2

ZIP/Postal Code

120 00

Country

Czechia

Facility Name

Research Site

City

Praha 3

ZIP/Postal Code

130 00

Country

Czechia

Facility Name

Research Site

City

Praha 4

ZIP/Postal Code

140 21

Country

Czechia

Facility Name

Research Site

City

Slany

ZIP/Postal Code

274 01

Country

Czechia

Facility Name

Research Site

City

Svitavy

ZIP/Postal Code

568 25

Country

Czechia

Facility Name

Research Site

City

Usti nad Orlici

ZIP/Postal Code

562 18

Country

Czechia

Facility Name

Research Site

City

Aalborg

ZIP/Postal Code

9000

Country

Denmark

Facility Name

Research Site

City

Ballerup

ZIP/Postal Code

2750

Country

Denmark

Facility Name

Research Site

City

Vejle

ZIP/Postal Code

7100

Country

Denmark

Facility Name

Research Site

City

Brest Cedex 2

ZIP/Postal Code

29200

Country

France

Facility Name

Research Site

City

Caen Cedex 9

ZIP/Postal Code

14033

Country

France

Facility Name

Research Site

City

Dijon

ZIP/Postal Code

21034

Country

France

Facility Name

Research Site

City

Le Creusot

ZIP/Postal Code

71200

Country

France

Facility Name

Research Site

City

Montpellier cedex 05

ZIP/Postal Code

34295

Country

France

Facility Name

Research Site

City

Nantes Cedex 1

ZIP/Postal Code

44093

Country

France

Facility Name

Research Site

City

Paris cedex 12

ZIP/Postal Code

75571

Country

France

Facility Name

Research Site

City

Paris

ZIP/Postal Code

75013

Country

France

Facility Name

Research Site

City

Poitiers

ZIP/Postal Code

86000

Country

France

Facility Name

Research Site

City

Strasbourg

ZIP/Postal Code

67091

Country

France

Facility Name

Research Site

City

Bad Krozingen

ZIP/Postal Code

79189

Country

Germany

Facility Name

Research Site

City

Berlin (Hellersdorf)

ZIP/Postal Code

12627

Country

Germany

Facility Name

Research Site

City

Berlin

ZIP/Postal Code

10367

Country

Germany

Facility Name

Research Site

City

Berlin

ZIP/Postal Code

10787

Country

Germany

Facility Name

Research Site

City

Freiburg

ZIP/Postal Code

79106

Country

Germany

Facility Name

Research Site

City

Heidelberg

ZIP/Postal Code

69120

Country

Germany

Facility Name

Research Site

City

Homburg

ZIP/Postal Code

66421

Country

Germany

Facility Name

Research Site

City

Leipzig

ZIP/Postal Code

04103

Country

Germany

Facility Name

Research Site

City

Magdeburg

ZIP/Postal Code

39104

Country

Germany

Facility Name

Research Site

City

Messkirch

ZIP/Postal Code

88605

Country

Germany

Facility Name

Research Site

City

Witten

ZIP/Postal Code

58455

Country

Germany

Facility Name

Research Site

City

Hong Kong

Country

Hong Kong

Facility Name

Research Site

City

New Territories

Country

Hong Kong

Facility Name

Research Site

City

Baja

ZIP/Postal Code

6500

Country

Hungary

Facility Name

Research Site

City

Berettyoujfalu

ZIP/Postal Code

4100

Country

Hungary

Facility Name

Research Site

City

Dunaujvaros

ZIP/Postal Code

2400

Country

Hungary

Facility Name

Research Site

City

Eger

ZIP/Postal Code

3300

Country

Hungary

Facility Name

Research Site

City

Gyongyos

ZIP/Postal Code

3200

Country

Hungary

Facility Name

Research Site

City

Hodmezovasarhely

ZIP/Postal Code

6800

Country

Hungary

Facility Name

Research Site

City

Jaszbereny

ZIP/Postal Code

5100

Country

Hungary

Facility Name

Research Site

City

Komarom

ZIP/Postal Code

2921

Country

Hungary

Facility Name

Research Site

City

Marcali

ZIP/Postal Code

8700

Country

Hungary

Facility Name

Research Site

City

Mosonmagyarovar

ZIP/Postal Code

9200

Country

Hungary

Facility Name

Research Site

City

Pecs

ZIP/Postal Code

7624

Country

Hungary

Facility Name

Research Site

City

Bologna

ZIP/Postal Code

40138

Country

Italy

Facility Name

Research Site

City

Cagliari

ZIP/Postal Code

09134

Country

Italy

Facility Name

Research Site

City

Chieti

ZIP/Postal Code

66100

Country

Italy

Facility Name

Research Site

City

Ferrara

ZIP/Postal Code

44124

Country

Italy

Facility Name

Research Site

City

Milano

ZIP/Postal Code

20162

Country

Italy

Facility Name

Research Site

City

Napoli

ZIP/Postal Code

80131

Country

Italy

Facility Name

Research Site

City

Padova

ZIP/Postal Code

35128

Country

Italy

Facility Name

Research Site

City

Perugia

ZIP/Postal Code

06129

Country

Italy

Facility Name

Research Site

City

Pisa

ZIP/Postal Code

56124

Country

Italy

Facility Name

Research Site

City

Trieste

ZIP/Postal Code

34149

Country

Italy

Facility Name

Research Site

City

Seoul

ZIP/Postal Code

120-752

Country

Korea, Republic of

Facility Name

Research Site

City

Seoul

ZIP/Postal Code

135-710

Country

Korea, Republic of

Facility Name

Research Site

City

Seoul

ZIP/Postal Code

138-736

Country

Korea, Republic of

Facility Name

Research Site

City

Suwon-si

ZIP/Postal Code

443-380

Country

Korea, Republic of

Facility Name

Research Site

City

Suwon

ZIP/Postal Code

443-721

Country

Korea, Republic of

Facility Name

Research Site

City

Mexico

State/Province

Distrito Federal

ZIP/Postal Code

03800

Country

Mexico

Facility Name

Research Site

City

Mexico

State/Province

Distrito Federal

ZIP/Postal Code

14000

Country

Mexico

Facility Name

Research Site

City

Leon

State/Province

Guanajuato

ZIP/Postal Code

37520

Country

Mexico

Facility Name

Research Site

City

Guadalajara

State/Province

Jalisco

ZIP/Postal Code

44100

Country

Mexico

Facility Name

Research Site

City

Guadalajara

State/Province

Jalisco

ZIP/Postal Code

44130

Country

Mexico

Facility Name

Research Site

City

Monterrey

State/Province

Nuevo LeÃ³n

ZIP/Postal Code

64460

Country

Mexico

Facility Name

Research Site

City

San Luis Potosi

State/Province

San Luis PotosÃ-

ZIP/Postal Code

78240

Country

Mexico

Facility Name

Research Site

City

Tampico

State/Province

Tamaulipas

ZIP/Postal Code

89000

Country

Mexico

Facility Name

Research Site

City

Durango

ZIP/Postal Code

34270

Country

Mexico

Facility Name

Research Site

City

Amsterdam

ZIP/Postal Code

1066 EC

Country

Netherlands

Facility Name

Research Site

City

Amsterdam

ZIP/Postal Code

1105 AZ

Country

Netherlands

Facility Name

Research Site

City

Den Helder

ZIP/Postal Code

1782 GZ

Country

Netherlands

Facility Name

Research Site

City

Groningen

ZIP/Postal Code

9728 NT

Country

Netherlands

Facility Name

Research Site

City

Hoogeveen

ZIP/Postal Code

7909 AA

Country

Netherlands

Facility Name

Research Site

City

Nieuwegein

ZIP/Postal Code

3435 CM

Country

Netherlands

Facility Name

Research Site

City

Nijmegen

ZIP/Postal Code

6525 GA

Country

Netherlands

Facility Name

Research Site

City

Rotterdam

ZIP/Postal Code

3045 PM

Country

Netherlands

Facility Name

Research Site

City

Waalwijk

ZIP/Postal Code

5141 BM

Country

Netherlands

Facility Name

Research Site

City

Zwijndrecht

ZIP/Postal Code

3331 LZ

Country

Netherlands

Facility Name

Research Site

City

Barnaul

ZIP/Postal Code

656055

Country

Russian Federation

Facility Name

Research Site

City

Kemerovo

ZIP/Postal Code

650002

Country

Russian Federation

Facility Name

Research Site

City

Moscow

ZIP/Postal Code

121002

Country

Russian Federation

Facility Name

Research Site

City

Moscow

ZIP/Postal Code

121552

Country

Russian Federation

Facility Name

Research Site

City

Moscow

ZIP/Postal Code

127299

Country

Russian Federation

Facility Name

Research Site

City

Novosibirsk

ZIP/Postal Code

630047

Country

Russian Federation

Facility Name

Research Site

City

Saint Petersburg

ZIP/Postal Code

192242

Country

Russian Federation

Facility Name

Research Site

City

Saint Petersburg

ZIP/Postal Code

197022

Country

Russian Federation

Facility Name

Research Site

City

Saint Petersburg

ZIP/Postal Code

197341

Country

Russian Federation

Facility Name

Research Site

City

Saint-Petersburg

ZIP/Postal Code

194156

Country

Russian Federation

Facility Name

Research Site

City

Saratov

ZIP/Postal Code

410054

Country

Russian Federation

Facility Name

Research Site

City

Alberton

State/Province

Gauteng

ZIP/Postal Code

1449

Country

South Africa

Facility Name

Research Site

City

Johannesburg

State/Province

Gauteng

ZIP/Postal Code

2196

Country

South Africa

Facility Name

Research Site

City

Lyttelton

State/Province

Gauteng

ZIP/Postal Code

0140

Country

South Africa

Facility Name

Research Site

City

Pretoria

State/Province

Gauteng

ZIP/Postal Code

0184

Country

South Africa

Facility Name

Research Site

City

Kuils River

State/Province

Western Cape

ZIP/Postal Code

7580

Country

South Africa

Facility Name

Research Site

City

Somerset West

State/Province

Western Cape

ZIP/Postal Code

7130

Country

South Africa

Facility Name

Research Site

City

Bloemfontein

ZIP/Postal Code

9301

Country

South Africa

Facility Name

Research Site

City

Cape Town

ZIP/Postal Code

7405

Country

South Africa

Facility Name

Research Site

City

Almeria

State/Province

AndalucÃ-a

ZIP/Postal Code

04001

Country

Spain

Facility Name

Research Site

City

AlmerÃ-a

State/Province

AndalucÃ-a

ZIP/Postal Code

04001

Country

Spain

Facility Name

Research Site

City

Barcelona

State/Province

CataluÃ±a

ZIP/Postal Code

08003

Country

Spain

Facility Name

Research Site

City

Barcelona

State/Province

CataluÃ±a

ZIP/Postal Code

08036

Country

Spain

Facility Name

Research Site

City

L'Hospitalet de Llobregat

State/Province

CataluÃ±a

ZIP/Postal Code

08907

Country

Spain

Facility Name

Research Site

City

Valencia

State/Province

Comunidad Valenciana

ZIP/Postal Code

46010

Country

Spain

Facility Name

Research Site

City

Pozuelo de Alarcon

State/Province

Madrid

ZIP/Postal Code

28223

Country

Spain

Facility Name

Research Site

City

Pozuelo De AlarcÃ³n

State/Province

Madrid

ZIP/Postal Code

28223

Country

Spain

Facility Name

Research Site

City

Madrid

ZIP/Postal Code

28007

Country

Spain

Facility Name

Research Site

City

Madrid

ZIP/Postal Code

28029

Country

Spain

Facility Name

Research Site

City

GÃ¶teborg

ZIP/Postal Code

413 45

Country

Sweden

Facility Name

Research Site

City

Lund

ZIP/Postal Code

222 21

Country

Sweden

Facility Name

Research Site

City

Lund

ZIP/Postal Code

222 22

Country

Sweden

Facility Name

Research Site

City

Stockholm

ZIP/Postal Code

171 45

Country

Sweden

Facility Name

Research Site

City

Uddevalla

ZIP/Postal Code

451 50

Country

Sweden

Facility Name

Research Site

City

Ã-rebro

ZIP/Postal Code

701 46

Country

Sweden

Facility Name

Research Site

City

Bellinzona

ZIP/Postal Code

6500

Country

Switzerland

Facility Name

Research Site

City

Geneva 14

ZIP/Postal Code

1211

Country

Switzerland

Facility Name

Research Site

City

Lausanne

ZIP/Postal Code

1011

Country

Switzerland

Facility Name

Research Site

City

Muensterlingen

ZIP/Postal Code

8596

Country

Switzerland

Facility Name

Research Site

City

St. Gallen

ZIP/Postal Code

9007

Country

Switzerland

Facility Name

Research Site

City

Zurich

ZIP/Postal Code

8063

Country

Switzerland

Facility Name

Research Site

City

Kaohsiung

ZIP/Postal Code

807

Country

Taiwan

Facility Name

Research Site

City

Kaohsiung

ZIP/Postal Code

83301

Country

Taiwan

Facility Name

Research Site

City

Taipei

ZIP/Postal Code

100

Country

Taiwan

Facility Name

Research Site

City

Birmingham

ZIP/Postal Code

B15 2SQ

Country

United Kingdom

Facility Name

Research Site

City

Blackpool

ZIP/Postal Code

FY3 7EN

Country

United Kingdom

Facility Name

Research Site

City

Cardiff

ZIP/Postal Code

CF14 5GJ

Country

United Kingdom

Facility Name

Research Site

City

Chesterfield

ZIP/Postal Code

S40 4TF

Country

United Kingdom

Facility Name

Research Site

City

Chorley

ZIP/Postal Code

PR7 7NA

Country

United Kingdom

Facility Name

Research Site

City

Doncaster

ZIP/Postal Code

DN9 1EP

Country

United Kingdom

Facility Name

Research Site

City

Glasgow

ZIP/Postal Code

G20 0SP

Country

United Kingdom

Facility Name

Research Site

City

Glasgow

ZIP/Postal Code

G45 9AW

Country

United Kingdom

Facility Name

Research Site

City

Harrow

ZIP/Postal Code

HA3 7LT

Country

United Kingdom

Facility Name

Research Site

City

Liverpool

ZIP/Postal Code

L22 0LG

Country

United Kingdom

Facility Name

Research Site

City

Liverpool

ZIP/Postal Code

L7 8XP

Country

United Kingdom

Facility Name

Research Site

City

Manchester

ZIP/Postal Code

M13 9WL

Country

United Kingdom

Facility Name

Research Site

City

Manchester

ZIP/Postal Code

M15 6SX

Country

United Kingdom

Facility Name

Research Site

City

Reading

ZIP/Postal Code

RG2 0FT

Country

United Kingdom

Facility Name

Research Site

City

Reading

ZIP/Postal Code

RG2 0TG

Country

United Kingdom

Facility Name

Research Site

City

Scunthorpe

ZIP/Postal Code

DN15 7BH

Country

United Kingdom

Facility Name

Research Site

City

Wakefield

ZIP/Postal Code

WF1 4DG

Country

United Kingdom

Facility Name

Research Site

City

Whitby

ZIP/Postal Code

YO21 1SD

Country

United Kingdom

12. IPD Sharing Statement

Citations:

PubMed Identifier

24825642

Citation

Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, Somaratne R, Legg JC, Nelson P, Scott R, Wasserman SM, Weiss R; LAPLACE-2 Investigators. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014 May 14;311(18):1870-82. doi: 10.1001/jama.2014.4030.

Results Reference

background

PubMed Identifier

24481874

Citation

Robinson JG, Rogers WJ, Nedergaard BS, Fialkow J, Neutel JM, Ramstad D, Somaratne R, Legg JC, Nelson P, Scott R, Wasserman SM, Weiss R. Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy. Clin Cardiol. 2014 Apr;37(4):195-203. doi: 10.1002/clc.22252. Epub 2014 Jan 30.

Results Reference

background

PubMed Identifier

33325247

Citation

Daviglus ML, Ferdinand KC, Lopez JAG, Wu Y, Monsalvo ML, Rodriguez CJ. Effects of Evolocumab on Low-Density Lipoprotein Cholesterol, Non-High Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a) by Race and Ethnicity: A Meta-Analysis of Individual Participant Data From Double-Blind and Open-Label Extension Studies. J Am Heart Assoc. 2021 Jan 5;10(1):e016839. doi: 10.1161/JAHA.120.016839. Epub 2020 Dec 16.

Results Reference

background

PubMed Identifier

32564340

Citation

Koren MJ, Jones PH, Robinson JG, Sullivan D, Cho L, Hucko T, Lopez JAG, Fleishman AN, Somaratne R, Stroes E. A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies. Cardiol Ther. 2020 Dec;9(2):447-465. doi: 10.1007/s40119-020-00181-8. Epub 2020 Jun 20.

Results Reference

background

PubMed Identifier

29736889

Citation

Kuchimanchi M, Grover A, Emery MG, Somaratne R, Wasserman SM, Gibbs JP, Doshi S. Population pharmacokinetics and exposure-response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia. J Pharmacokinet Pharmacodyn. 2018 Jun;45(3):505-522. doi: 10.1007/s10928-018-9592-y. Epub 2018 May 7.

Results Reference

background

PubMed Identifier

29353350

Citation

Kasichayanula S, Grover A, Emery MG, Gibbs MA, Somaratne R, Wasserman SM, Gibbs JP. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. Clin Pharmacokinet. 2018 Jul;57(7):769-779. doi: 10.1007/s40262-017-0620-7.

Results Reference

background

PubMed Identifier

30755061

Citation

Shapiro MD, Minnier J, Tavori H, Kassahun H, Flower A, Somaratne R, Fazio S. Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab. J Am Heart Assoc. 2019 Feb 19;8(4):e010932. doi: 10.1161/JAHA.118.010932.

Results Reference

background

PubMed Identifier

30120772

Citation

Stroes E, Robinson JG, Raal FJ, Dufour R, Sullivan D, Kassahun H, Ma Y, Wasserman SM, Koren MJ. Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies. Clin Cardiol. 2018 Oct;41(10):1328-1335. doi: 10.1002/clc.23049. Epub 2018 Oct 21.

Results Reference

background

PubMed Identifier

28249876

Citation

Toth PP, Descamps O, Genest J, Sattar N, Preiss D, Dent R, Djedjos C, Wu Y, Geller M, Uhart M, Somaratne R, Wasserman SM; PROFICIO Investigators. Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies. Circulation. 2017 May 9;135(19):1819-1831. doi: 10.1161/CIRCULATIONAHA.116.025233. Epub 2017 Mar 1.

Results Reference

background

PubMed Identifier

32114889

Citation

Toth PP, Jones SR, Monsalvo ML, Elliott-Davey M, Lopez JAG, Banach M. Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies. J Am Heart Assoc. 2020 Mar 3;9(5):e014129. doi: 10.1161/JAHA.119.014129. Epub 2020 Mar 2.

Results Reference

background

PubMed Identifier

29768954

Citation

Wasserman SM, Sabatine MS, Koren MJ, Giugliano RP, Legg JC, Emery MG, Doshi S, Liu T, Somaratne R, Gibbs JP. Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications. J Cardiovasc Pharmacol Ther. 2018 Sep;23(5):423-432. doi: 10.1177/1074248418774043. Epub 2018 May 16.

Results Reference

background

PubMed Identifier

30852766

Citation

May HT, Muhlestein JB, Ma Y, Lopez JAG, Coll B, Nelson J. Effects of Evolocumab on the ApoA1 Remnant Ratio: A Pooled Analysis of Phase 3 Studies. Cardiol Ther. 2019 Jun;8(1):91-102. doi: 10.1007/s40119-019-0133-6. Epub 2019 Mar 9.

Results Reference

background

Links:

URL

http://www.amgentrials.com

Description

AmgenTrials clinical trials website

Learn more about this trial

LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2

We'll reach out to this number within 24 hrs

LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2 (LAPLACE-2)

Hyperlipidemia

About this trial

Eligibility Criteria

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm 10

Arm 11

Arm 12

Arm 13

Arm 14

Arm 15

Arm 16

Arm 17

Arm 18

Arm 19

Arm 20

Arm 21

Arm 22

Arm 23

Arm 24

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

1. Study Identification

2. Study Status

3. Sponsor/Collaborators

4. Oversight

5. Study Description

6. Conditions and Keywords

7. Study Design

8. Arms, Groups, and Interventions

10. Eligibility

12. IPD Sharing Statement

Learn more about this trial